Latest Sustainability In It News

Xero Limited reported a robust FY25 with 23% revenue growth and a 22% rise in adjusted EBITDA, underpinned by subscriber and ARPU gains across key markets. The company is doubling down on AI integration and disciplined capital allocation to sustain momentum.

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.

Xero Limited reported a robust FY25 with 23% revenue growth to NZ$2.1 billion and a 30% rise in net profit, driven by strategic investments in AI and product innovation. Leadership changes and a CEO pay review underscore the company’s global ambitions.

Orora Limited announces a leadership transition in its Global Glass division, with Emmanuel Ladent set to succeed Jean Marc Arrambourg as President by year-end 2025.

MedAdvisor Limited has successfully closed its Share Purchase Plan, raising $2.668 million-exceeding its $2 million target-and plans an upcoming shareholder meeting to approve director share issuances.

Orora Limited has unveiled a strategic update highlighting robust growth in its beverage packaging segments, underpinned by strong cans volume expansion and targeted glass network optimisations. The company projects steady earnings and disciplined capital allocation through FY25 and beyond.

Minbos Resources advances its Cabinda Phosphate Project with strong sales interest and a $36 million financing package, positioning itself as a key player in Angola's agricultural transformation.

PVW Resources reports promising assay results from its Capão Bonito rare earth project and expands exploration efforts across Brazil, bolstered by new metallurgical expertise.

WA1 Resources has reported outstanding assay results from its Luni niobium deposit, highlighting some of the highest grades to date and setting the stage for an updated Mineral Resource estimate in June.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Euro Manganese Inc. reported a net loss of CAD 9.174 million for the half-year ending March 31, 2025, while making significant progress on its Chvaletice Manganese Project, including securing key permits and strategic status under EU and Czech frameworks. The company’s development hinges on completing a crucial private placement and share purchase plan to sustain operations.

Euro Manganese advances its Chvaletice manganese project with key regulatory approvals, leadership appointments, and a $9.8 million capital raise, while reporting a narrowed Q3 net loss.